Unity Biotechnology, Inc. (UBX): Price and Financial Metrics
GET POWR RATINGS... FREE!
UBX Stock Price Chart Interactive Chart >
UBX Price/Volume Stats
|Current price||$0.85||52-week high||$5.09|
|Prev. close||$0.79||52-week low||$0.70|
|Day high||$0.85||Avg. volume||778,460|
|50-day MA||$1.00||Dividend yield||N/A|
|200-day MA||$1.89||Market Cap||58.79M|
Unity Biotechnology, Inc. (UBX) Company Bio
Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is based in Brisbane, California.
Most Popular Stories View All
UBX Latest News Stream
|Loading, please wait...|
UBX Latest Social Stream
View Full UBX Social Stream
Latest UBX News From Around the Web
Below are the latest news stories about Unity Biotechnology Inc that investors may wish to consider to help them evaluate UBX as an investment opportunity.
UNITY Biotechnology <
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company de
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $12.00. The company's shares closed last Monday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -3.2% and a 34.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $7.00. The company's shares closed last Friday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -14.1% and a 37.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $5.00 average price target, implying a 371.
The quest to ease the pain of aging baby boomers and future generations hasn't translated into much clinical success. But as pioneering aging disease companies switch gears, startups continue to jump in.
UBX Price Returns